The US Food and Drug Administration announced the approval Wednesday of the new weightloss drug Contrave a mix of antidepressant and alcohol dependence medications The drug which is intended to be used along with a lowcalorie diet and exercise regimen is approved for use in obese adults body mass index of  or greater or overweight adults BMI of  or greater who also suffer a weightrelated condition such as high blood pressure or Type  diabetes according to regulators The medication which is manufactured by Orexigen Therapeutics Inc of La Jolla combines the drugs naltrexone which is used to treat alcohol and opioid dependence and the drug bupropion which is prescribed for depression seasonal affective disorder and smoking cessation Orexigen initially sought approval from the FDA in  but was asked to conduct further testing on the drugs cardiovascular risks About onethird of Americans are classified as obese and Dr JeanMarc Guettier director of the FDAs division of metabolism and endocrinology products said Contrave can help address this national problem Clinical trials designed to test Contraves effectiveness involved  obese and overweight patients who were treated for one year In one trial  of patients who received the drug lost at least  of their body weight and  of the patients who received a placebo experienced similar results In a trial that involved patients suffering from Type  diabetes  of Contravetreated patients lost at least  of their weight compared with  of patients who received a placebo the FDA said The drug comes with a number of cautions A boxed warning will alert healthcare providers to an increased risk of suicidal thoughts and behaviors associated with antidepressant drugs Contrave can cause seizures and must not be used in patients who have seizure disorders read an FDA news release Contrave can also raise blood pressure and heart rate and must not be used in patients with uncontrolled high blood pressure The drug should also not be used in patients who have eating disorders such as bulimia or anorexia nervosa the FDA said